Seven Fleet Capital Management LP Buys 10,252 Shares of Celcuity, Inc. $CELC

Seven Fleet Capital Management LP boosted its stake in shares of Celcuity, Inc. (NASDAQ:CELC) by 170.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,252 shares of the company’s stock after buying an additional 10,252 shares during the quarter. Seven Fleet Capital Management LP’s holdings in Celcuity were worth $1,700,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Creative Planning acquired a new stake in shares of Celcuity in the second quarter valued at about $177,000. Rhumbline Advisers lifted its stake in shares of Celcuity by 1.2% in the second quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock worth $570,000 after acquiring an additional 503 shares during the period. XTX Topco Ltd acquired a new position in shares of Celcuity in the second quarter worth approximately $169,000. Quantinno Capital Management LP boosted its holdings in Celcuity by 20.7% in the second quarter. Quantinno Capital Management LP now owns 243,042 shares of the company’s stock valued at $3,245,000 after acquiring an additional 41,756 shares during the last quarter. Finally, Paloma Partners Management Co boosted its holdings in Celcuity by 285.8% in the second quarter. Paloma Partners Management Co now owns 82,137 shares of the company’s stock valued at $1,097,000 after acquiring an additional 60,849 shares during the last quarter. Institutional investors own 63.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Stifel Nicolaus decreased their target price on shares of Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Guggenheim upped their price objective on shares of Celcuity from $165.00 to $175.00 and gave the company a “buy” rating in a research note on Monday, August 17th. Craig Hallum reiterated a “buy” rating and set a $178.00 price objective on shares of Celcuity in a research report on Wednesday, July 15th. Citizens Jmp reissued a “market outperform” rating and set a $177.00 target price on shares of Celcuity in a research note on Monday, August 17th. Finally, HC Wainwright restated a “buy” rating and issued a $155.00 target price on shares of Celcuity in a report on Friday, August 14th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $154.55.

Celcuity Trading Up 3.0%

Shares of CELC stock opened at $95.08 on Thursday. The company has a market cap of $4.65 billion, a P/E ratio of -22.11 and a beta of 0.20. The stock has a 50 day simple moving average of $94.52 and a two-hundred day simple moving average of $107.38. The company has a debt-to-equity ratio of 6.04, a quick ratio of 8.93 and a current ratio of 8.93. Celcuity, Inc. has a fifty-two week low of $44.42 and a fifty-two week high of $151.02.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). Research analysts forecast that Celcuity, Inc. will post -4.75 earnings per share for the current year.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.